Indraprastha Medical Q1 Revenue Rises To ₹410 Crore, Net Profit At ₹55.9 Crore

Market snapshot: Indraprastha Medical Corporation Limited has reported a strong set of standalone financial results for the first quarter of the fiscal year ending March 31, 2027. Standalone net profit grew to ₹55.9 crore, up from ₹51.5 crore in the same period last year. Revenue for the quarter expansion reached ₹410 crore from ₹370 crore YoY, showcasing continued operating momentum.

Data Snapshot

• Standalone revenue for Q1 grew to ₹410 crore compared to ₹370 crore in the previous year's corresponding quarter.
• Standalone net profit for the quarter rose to ₹55.9 crore against ₹51.5 crore YoY.
• EBITDA rose to ₹79.8 crore from ₹72.6 crore in the year-ago period, while the EBITDA margin stood at 19.65% compared to 19.89% YoY.

What's Changed

• Standalone net profit increased by ≈8.54% YoY (derived: ₹55.9 crore vs ₹51.5 crore).
• Standalone revenue expanded by ≈10.81% YoY (derived: ₹410 crore vs ₹370 crore).
• Absolute EBITDA grew by ≈9.92% YoY (derived: ₹79.8 crore vs ₹72.6 crore).
• EBITDA margin compressed marginally by 24 basis points YoY to 19.65% from 19.89%.

Key Takeaways

• Revenue growth of ≈10.81% YoY points to healthy inpatient and outpatient patient volumes across flagship hospitals.
• Absolute operational income performance remains solid, as evidenced by a ≈9.92% growth in EBITDA to ₹79.8 crore.
• The bottom-line continues to expand steadily without being burdened by interest expenses due to the company's long-term debt-free status.
• Despite cost inflation in doctor fees and medical supplies, EBITDA margins stayed highly competitive at 19.65%.

SAHI Perspective

Indraprastha Medical Corporation's performance reflects stable operational fundamentals. The double-digit expansion of revenues by ≈10.81% suggests a high bed-occupancy rate at its core tertiary care center in Delhi. Although there was a marginal 24 bps compression in the EBITDA margin, absolute operational profitability was well-maintained. The absence of interest overheads on its balance sheet ensures high net margin retention, positioning the company well for sustained cash generation.

Market Implications

The stable financial numbers will likely preserve investor interest in the stock. The consistent bottom-line performance provides strong visibility for maintaining healthy payout levels. A final dividend of ₹4.00 per share has already been proposed for the preceding financial year, and the upcoming record date of August 14, 2026, makes the stock highly relevant for income-focused portfolios.

Trading Signals

Market Bias: Bullish

Indraprastha Medical's Q1 results are characterized by resilient revenue growth (up ≈10.81% to ₹410 crore) and a stable standalone net profit growth of ≈8.54% to ₹55.9 crore. Operational performance remains protected by a net debt-free capital structure.

Overweight: Hospitals & Healthcare, Healthcare Facilities

Trigger Factors:

• Consistent bed occupancy levels and inpatient volumes in the NCR.
• Stabilization of EBITDA margins above the 19.5% threshold.
• Payout dynamics post the August 14, 2026 dividend record date.

Time Horizon: Near-term (0-3 months)

Industry Context

The healthcare facilities industry in India is supported by structural tailwinds, including increasing demographic demand, higher health insurance adoption among middle-income groups, and specialized tertiary healthcare requirements. Operating as a joint venture with Apollo Hospitals (holding ≈22%) and the Delhi Government (holding ≈26%) allows Indraprastha Medical to maintain a dominant footprint in the Delhi National Capital Region.

Key Risks to Watch

• Minor margin pressures reflecting general inflation in nursing and clinical staff costs.
• Regulatory overhangs related to clinical procedure pricing in the Delhi-NCR territory.
• High geographical concentration, with a single flagship hospital driving the vast majority of operations.

Recent Developments

On June 29, 2026, the company's board approved the appointment of M/s. Abhishek Jain & Associates as the new Secretarial Auditors for a five-year term starting from FY 2026-27. Additionally, the final dividend of ₹4.00 per share recommended on May 11, 2026, is progressing toward its ex-dividend date with the record date set for August 14, 2026.

Closing Insight

With steady double-digit revenue growth and complete insulation from debt costs, Indraprastha Medical Corporation remains a structurally sound hospital operator in the premium healthcare segment, maintaining robust capital efficiency and shareholder returns.

High Performance Trading with SAHI.